RxDoctor Payments Data

Andrew Dorizas, MD

Dermatology · West Palm Beach, FLNPI 1336506260

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $616,602 of the $896,519 with a category attached, or 68.8%. 43 manufacturers reported payments, led by Johnson & Johnson at 29.4% of the total. 2025 is the largest year on record at $578,425, more than ten times the $1,619 reported in 2019. Among dermatology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$896,519in general payments, 2019–2025

Across 1,508 payments — averaging $594.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$264K
  • UCB, Inc.$118K
  • Lilly USA, LLC$106K
  • LEO Pharma Inc.$85K
  • Arcutis Biotherapeutics, Inc.$70K
  • Incyte Corporation$56K
  • plus $199K from 37 others

What the payments were for

  • Consulting fees$130,67015%
  • Speaking & faculty fees$616,60269%
  • Travel & lodging$105,08212%
  • Food & beverage$43,9935%
  • Education$1720%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$896,519 in reported general payments places this provider in the 95th percentile of 1,147 dermatology providers in Florida.

See all dermatology providers in Florida

Medicare billing

Part B allowed, 2024
$355,878
Medicare patients
812
Services billed
3,231

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab63$248,486
Dupixent SyringeDupilumab11$39,902
KlisyriTirbanibulin11$13,876
Clobetasol Propionate101$4,116
Ketoconazole203$3,095
Tacrolimus16$1,873
Triamcinolone Acetonide82$919
Ciclopirox26$814
Tretinoin11$808
Clindamycin Phosphate31$766
Fluorouracil11$717
Doxycycline Hyclate46$533
Hydrocortisone82$498
Mupirocin76$496
Dutasteride25$471

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Almirall LLCKlisyri$17,206$13,87611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,147 dermatology providers in Florida.

Other dermatology in West Palm Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →